SELECTRA is pleased to announce that the J. Lamarck Biotech Sub-Fund (the “Fund”) received a ***** (5-star) Morningstar RatingTM for its institutional “C” fund class.
The USD denominated class of the J. Lamarck sub-fund received an Overall five-star Morningstar Rating™ as of August 31, 2017 based on risk-adjusted returns for the 3-year period. The Morningstar Rating™, commonly known as the star rating, rates mutual funds from one to five stars, with the best performers receiving five stars. The rating is an assessment of a fund’s past performance – based on both return and risk – which shows how similar investments compare with their competitors. The J. Lamarck Biotech Sub-Fund is rated within the top 10% of the Sector Equity Biotechnology category, which only includes funds investing at least 75% of total assets in equities and invest at least 50% of equity assets in the biotechnology industry.
Launched on June 20, 2014, the Fund seeks to profit from increasing share prices in the biotechnology sector. The strategy focuses on achieving total returns that are greater than that of the overall equity market with less risk.
“We are pleased that Morningstar has recognized J. Lamarck sub-fund with a 5-star Morningstar Rating™,” said Marco Cipolla, Funding Partner at Selectra. “This 5-star, highest-possible rating from Morningstar is an example of our process driven investment approach, which produces strong results for our clients over the long term”.
“We are very proud that we have received this 5 star Morningstar Rating,” added Eugene Hardonk, CEO of J. Lamarck S.p.A., the advisor of the fund. “This confirms the hard work of our skilled investment team and shows it is possible to combine the potential of the biotech sector with the mitigation of risk”.
The Fund is marketed to financial professionals by Selectra, which is a premier investment company based in Luxembourg. Additional details on fund performance and investment specifics are available at the Selectra website: www.selectra.lu.